Additionally, the expression level of HSF1 was observed to be enhanced in chronic lymphocytic leukemia (CLL) and decreased in patients responding to in the rituximab–bendamustine protocol [17], which supports its potential to be a biomarker for efficacy prediction. This evidence concerns the gene HSF1 and B-cell chronic lymphocytic leukemia.